MedTrace Logo

A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever

NCT05108545 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2021-11-05

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever.

Conditions

  • Neutropenia and Fever

Interventions

DRUG

Amphotericin B liposomes

Amphotericin B liposomes for injection, 3 mg/kg, qd, IV

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2022-07-31
Completion
2023-01-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05108545 on ClinicalTrials.gov